Vitiligo Management
For adults with recent-onset vitiligo, initiate treatment with a potent or very potent topical corticosteroid for a trial period of no more than 2 months, with topical calcineurin inhibitors (pimecrolimus or tacrolimus) as alternatives when steroid side effects are a concern. 1
Initial Assessment and Diagnosis
The diagnosis is straightforward in classical symmetrical presentations and can be made confidently in primary care. Atypical presentations require dermatologist assessment 1. Check thyroid function given the high prevalence of autoimmune thyroid disease in vitiligo patients 1. Document skin type and photograph the extent of disease; Wood's light can monitor treatment response 1.
Treatment Algorithm by Patient Profile
Adults with Skin Types I-II (Very Fair Skin)
For patients with minimal cosmetic concern, consider no active treatment beyond camouflage cosmetics and sunscreens after thorough discussion 1. This is a legitimate first-line approach when vitiligo causes little distress in pale-skinned individuals.
First-Line Topical Therapy (All Adults)
Potent or very potent topical corticosteroids for ≤2 months are the primary treatment for recent-onset vitiligo 1. The evidence shows benefits but skin atrophy is a common side effect, necessitating the strict 2-month limit.
Topical pimecrolimus is the preferred alternative to corticosteroids, particularly for symmetrical vitiligo, with a superior side-effect profile compared to highly potent steroids 1. While based on limited evidence (one study), the safety advantage makes this a reasonable choice for facial involvement or when prolonged treatment is anticipated.
Phototherapy Indications
Narrowband UVB (NB-UVB) should be used preferentially over PUVA for widespread vitiligo or localized disease with significant quality of life impact 1. Reserve phototherapy for patients who cannot be adequately managed with topical treatments 1.
Key phototherapy principles:
- NB-UVB demonstrates superior efficacy to oral PUVA with better color matching of repigmented skin 1
- Ideal for darker skin types (III-VI) 1
- Monitor with serial photographs every 2-3 months 1
- Safety limits: maximum 200 NB-UVB treatments for skin types I-III; 150 PUVA treatments for skin types I-III 1
- Evidence lacking for upper limits in skin types IV-VI 1
Critical caveat: PUVA shows sustained improvement at 12 months in <25% of patients, and some patients worsen during treatment 1. Hands and feet respond poorly regardless of modality 1.
Surgical Interventions
Reserve surgical treatments exclusively for cosmetically sensitive sites with stable disease: no new lesions, no Koebner phenomenon, and no lesion extension for the previous 12 months 1. This stability criterion is essential to avoid poor outcomes.
Split-skin grafting is superior to minigraft procedures in both cosmetic results and repigmentation 1. Minigraft is explicitly not recommended due to high side-effect incidence and poor cosmetic outcomes 1.
Autologous epidermal suspension applied to laser-abraded lesions followed by phototherapy represents the optimal surgical approach but requires specialized facilities 1.
Depigmentation Therapy
Depigmentation with monobenzyl ether of hydroquinone (MBEH) is reserved exclusively for adults with >50% depigmentation or extensive facial/hand involvement who cannot or will not pursue repigmentation and accept permanent inability to tan 1. This is an irreversible decision requiring careful patient selection and cultural consideration.
Systemic Therapy
Oral dexamethasone cannot be recommended due to unacceptable side-effect risk despite potential to arrest progression 1. The risk-benefit ratio does not support its use.
Pediatric Considerations
For children, topical pimecrolimus or tacrolimus should be considered as alternatives to highly potent topical steroids given their better short-term safety profile 1. The same 2-month limit applies to potent/very potent steroids in children 1.
NB-UVB is preferred over PUVA in children due to greater efficacy, safety, and lack of pediatric PUVA trials 1. PUVA is not recommended in children 1.
Surgical treatment is not recommended in children due to absence of supporting studies 1.
Psychological Support
Psychological interventions should be offered to improve coping mechanisms in all patients with vitiligo 1. For children, parents should also receive psychological counseling 1. The psychosocial burden—including low self-esteem, social anxiety, depression, and stigmatization—is substantial and requires direct attention.
Common Pitfalls to Avoid
- Do not exceed 2 months of potent/very potent topical steroid use due to atrophy risk 1
- Do not use minigraft procedures—they have poor outcomes 1
- Do not perform surgery on active or unstable disease—wait for 12 months of stability 1
- Do not use oral dexamethasone—side effects outweigh benefits 1
- Do not offer depigmentation to patients seeking repigmentation or those unable to accept permanent changes 1
Emerging Evidence
Recent guidelines 2, 3, 4 emphasize shared decision-making and disease activity assessment as cornerstones of management. The approval of topical JAK inhibitors (ruxolitinib 1.5% cream) represents the first specifically approved vitiligo therapy 5, though the 2008 British guidelines remain the primary evidence base provided here.